ArticleChinese medicine2021
Integrated Chinese and western medicine interventions for atopic dermatitis: a systematic review and meta-analysis.
Article in Chinese medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 12 citations in OpenAlex.
- Mechanism of Gu-Ben-Hua-Shi (AESS) Formula Regulating Autophagy Through Hippo-YAP Pathway in Restoring the Skin Barrier in Atopic Dermatitis.Journal of cellular and molecular medicine · 2026Observational
- Clinical evidence on integrated Chinese-Western medicine for atopic dermatitis.Integrative medicine research · 2026Article
- Mechanisms of pruritus and advances in traditional Chinese medicine therapy (Review).Molecular medicine reports · 2026Review
- Efficacy of herbal medicine Xiao-Feng-San combined with auricular acupuncture for atopic dermatitis: A randomized controlled trial.Integrative medicine research · 2026Article
- Adjunctive Use of VGH4 for Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Trial.Life (Basel, Switzerland) · 2026Article
- Bibliometric Analysis of Traditional Chinese Medicine in Treating Eczema.Clinical, cosmetic and investigational dermatology · 2026Review
- Comparison of the Effectiveness Differences between Western and Chinese Medicinal Ointments against Eczema.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Family Members' Perspectives on Integrative Chinese-Western Medicine in Cancer Care.Journal of multidisciplinary healthcare · 2025Article
- Efficacy of Fuzhiqing ointment in mild-to-moderate atopic dermatitis: protocol for a multicenter, randomized, double-blind, placebo-controlled trial.Frontiers in medicine · 2025Article
- Analysis of the correlation between the levels of HIF-1α and miR-199a in lesions and the psoriasis severity index.Postepy dermatologii i alergologii · 2024Article
- Insights from Traditional Chinese Medicine for Restoring Skin Barrier Functions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Integrating Acupuncture into a Dialysis Center.Healthcare (Basel, Switzerland) · 2023Article
- Compound traditional Chinese medicine dermatitis ointment ameliorates inflammatory responses and dysregulation of itch-related molecules in atopic dermatitis.Chinese medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is a chronic relapsing skin disease characterized by recurring episodes of itchiness with skin erythema and surface damages. Chinese medicine (CM) is widely used for the management of AD in China not only by its own, but also used in combination with conventional therapy (integrated Chinese-Western medicine, ICWM). Although many clinical trials on the effectiveness of ICWM on AD have been conducted, however, up to date, no sound evidence has been established on the clinical effectiveness and safety of ICWM for AD.
objectivesTo systematically review the currently available clinical evidence on the clinical effectiveness and safety of ICWM for AD.
methodsRandomised and quasi-randomised controlled trials, which investigated ICWM interventions with at least one control group using the same conventional interventions, no treatment or placebo treatment, were included. Four English (CENTRAL, MEDLINE, EMBASE, AMED) and three Chinese (CNKI, CBM, WanFang Med) databases were searched. Risk of bias was assessed according to the Cochrane's tool. Meta-analysis was performed to pool the data.
resultsFrom 1473 entries, 55 studies were included, involving 5953 participants aged between 35 days and 67 years old. Duration of treatment ranged from 1 to 24 weeks. Only 2 studies were judged to have low risk of bias, 3 studies had unclear risk of bias, and the other 50 studies were with high risk of bias. ICWM was found to be superior over WM alone in improving clinical severity of AD (measured by EASI, SCORAD), health-related quality of life (measured by CDLQI, DLQI), long term control of AD (recurrence rate), patients/investigator global score (clinical effectiveness rate), and serum IgE level. Adverse events associated with ICWM were found to be comparable with WM alone.
conclusionICWM seems to produce superior treatment response than WM alone in managing AD without increased risk of adverse events. However, the current available evidence remains too weak to make a conclusive decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.